Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $79,548 | -18.1% | 14,596 | +2.0% | 0.00% | – |
| Q2 2023 | $97,138 | +35.5% | 14,306 | 0.0% | 0.00% | – |
| Q1 2023 | $71,673 | +2.7% | 14,306 | 0.0% | 0.00% | – |
| Q4 2022 | $69,813 | -68.0% | 14,306 | -5.2% | 0.00% | -100.0% |
| Q3 2022 | $218,000 | -4.4% | 15,096 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $228,000 | +71.4% | 15,096 | +35.3% | 0.00% | – |
| Q1 2022 | $133,000 | -26.5% | 11,156 | 0.0% | 0.00% | – |
| Q4 2021 | $181,000 | -42.4% | 11,156 | +1.2% | 0.00% | -100.0% |
| Q3 2021 | $314,000 | -15.6% | 11,019 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $372,000 | +39.3% | 11,019 | +24.6% | 0.00% | 0.0% |
| Q1 2021 | $267,000 | -38.1% | 8,845 | +1.5% | 0.00% | 0.0% |
| Q4 2020 | $431,000 | +28.7% | 8,715 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $335,000 | -4.8% | 8,715 | +7.0% | 0.00% | 0.0% |
| Q2 2020 | $352,000 | – | 8,145 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |